MNG78
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.545
- WNT_BETA_CATENIN_SIGNALING+0.406
- HYPOXIA+0.383
- TGF_BETA_SIGNALING+0.354
- HEDGEHOG_SIGNALING+0.326
- MITOTIC_SPINDLE+0.306
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.303
- APOPTOSIS+0.268
- IL6_JAK_STAT3_SIGNALING+0.264
- IL2_STAT5_SIGNALING+0.256
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.396
- MYC_TARGETS_V2-0.281
- PEROXISOME-0.269
- BILE_ACID_METABOLISM-0.245
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.227
- PANCREAS_BETA_CELLS-0.210
- MTORC1_SIGNALING-0.202
- UNFOLDED_PROTEIN_RESPONSE-0.199
- XENOBIOTIC_METABOLISM-0.183
- FATTY_ACID_METABOLISM-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG454 | — | — | 0.782 |
| 2 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.776 |
| 3 | TCGA-A2-A4RX-01A-11R-A266-07 | — | D | 0.766 |
| 4 | 156a3def-5866-4be4-ad0b-61b957d5b6eb | — | — | 0.766 |
| 5 | SAMN03290934 | — | — | 0.758 |
| 6 | SRR27320698 | — | — | 0.754 |
| 7 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.752 |
| 8 | DRR168609 | — | — | 0.750 |
| 9 | TCGA-EW-A6SC-01A-12R-A32P-07 | — | A | 0.749 |
| 10 | TCGA-A8-A08Z-01A-21R-A00Z-07 | — | A | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.545 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.406 | Inavolisib | — uncovered |
| HYPOXIA | 0.383 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.354 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.326 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.306 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.303 | Inavolisib | — uncovered |
| APOPTOSIS | 0.268 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.264 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.256 | Idelalisib | — uncovered |
| COMPLEMENT | 0.198 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.192 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.188 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.181 | Inavolisib | — uncovered |
| COAGULATION | 0.178 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.174 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.167 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.142 | Idelalisib | — uncovered |
| MYOGENESIS | 0.116 | Inavolisib | — uncovered |